CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 455 enrolled
Drug / intervention
SM04690 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02536833
NCT02536833Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Biosplice Therapeutics, Inc.·interventional·Posted Sep 1, 2015·Updated Mar 17, 2021

In Brief

A Phase 2 clinical trial evaluating SM04690 and Placebo for Osteoarthritis. Completed, enrolled 455 participants across 36 sites.

Detailed Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of three different strengths of SM04690 injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 1, 2015
Enrollment StartSep 9, 2015
Primary CompletionApr 20, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.8 years ago

Interventions

SM04690drug

Placebodrug